Appointments are available within an hour, ensuring you can receive care when you need it most
It is indicated for adults with obesity (BMI of 30 kg/m^2 or greater) and adults who are overweight (BMI of 27 kg/m^2 or greater) with at least one weight-related medical condition, such as high blood pressure, T2D, or dyslipidemia
Educational framing keeps expectations realistic and clinically grounded
Mechanistically, GLP-1 receptor agonists improve endothelial function, cause vasodilation, reduce systemic vascular resistance, lower blood pressure, reduce inflammation, and favorably affect lipid profiles
for example, clinical trials show constipation occurs in approximately 24% of patients taking Wegovy (semaglutide 2.4mg), with lower rates typically seen with dulaglutide and standard-dose semaglutide
The product type segment is divided into semaglutide, liraglutide, exenatide, dulaglutide, and others, with semaglutide taking the lead in 2024 with a market share of 58.4%